OrbiMed, Wellington backers of Chinese biotech Gracell

Wellington Management Company and Morningside Ventures joined healthcare investment specialists OrbiMed and Vivo Capital to lead a $100 million Series C round for Gracell Biotechnologies.

"We are very pleased to expand our investor base with support from a high caliber consortium," said Dr. William Wei Cao, founder, chairman, and CEO of Gracell, "Our passion is to bring transformative CAR-T cell therapies to a broader group of patients by developing products that are efficacious and can be made widely available."

Joining fellow existing investor OrbiMed, Temasek Holdings, Lilly Asia Ventures and King Star Med . . .

Continue Reading

Unlock this article instantly, along with the rest of our premium content, newsletters and data tables tracking investor and manager activity. Annual subscriptions get you the most bang for your buck, including access to Alternatives Watch Research articles and out Annual Investor Compendium.

Monthly subscriptions and discounted corporate plans for up to 100 members also available.

Sergio Barreto

Sergio Barreto is about 70% journalist, 30% tech geek. As an editor for The ABIS Group, he produces daily newsletters for leading healthcare and technology companies. With BMV Digital, he provides WordPress-based web developments services. Here at Alternatives Watch, he wears both hats - handling IT and occasionally writing about the intersection of alts, healthcare and tech.

Related Articles

Back to top button

Start Your Days in the Know


Get fresh alts intel in your inbox with our FREE newsletter!

You have Successfully Subscribed!